English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
Shares of Major Global Medical Device Manufacturer OrbusNeich Medical Group Commence Trading on the Main Board of The Stock Exchange of Hong Kong
Dec 23, 2022 15:10 HKT
노보텍, 생명공학 쇼케이스 2023의 골드 스폰서
Dec 21, 2022 07:00 HKT
Sirnaomics公布RNAi治疗药物STP707用于治疗多种实体瘤的临床I期试验中期数据
Dec 20, 2022 23:58 HKT
Sirnaomics公佈RNAi治療藥物STP707用於治療多種實體瘤的臨床I期試驗中期數據
Dec 20, 2022 23:57 HKT
Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
Dec 20, 2022 23:56 HKT
Pharmaron: Fulfilling the 'Green' and 'Low-carbon' Mission, Striving to Improve Sustainability
Dec 20, 2022 20:50 HKT
科技報國顯民企擔當 凱普生物領跑分子診斷行業
Dec 20, 2022 20:30 HKT
Novotech 是 Biotech Showcase 2023 的金牌赞助商
Dec 20, 2022 15:00 HKT
Novotech 是 Biotech Showcase 2023 的金牌贊助商
Dec 20, 2022 15:00 HKT
Novotech is Gold Sponsor at Biotech Showcase 2023
Dec 20, 2022 11:00 HKT
TANAKA Contributes to Venture Capital Fund "DMC No. 1 Investment Limited Partnership" Aiming to Establish a Medical Venture Ecosystem in Japan
Dec 20, 2022 10:00 HKT
田中贵金属工业对旨在确立日本的医疗风险企业生态系统的风险投资基金“DMC1号投资事业有限责任组合”进行出资
Dec 20, 2022 10:00 HKT
田中贵金属工业对旨在确立日本的医疗风险企业生态系统的风险投资基金“DMC1号投资事业有限责任组合”进行出资
Dec 20, 2022 10:00 HKT
다나까귀금속공업 일본 의료 벤처 에코 시스템 확립을 목표로 하는 벤처 캐피털 펀드 ‘DMC 1호 투자 사업 유한 책임 조합’에 출자
Dec 20, 2022 10:00 HKT
다나까귀금속공업 일본 의료 벤처 에코 시스템 확립을 목표로 하는 벤처 캐피털 펀드 ‘DMC 1호 투자 사업 유한 책임 조합’에 출자
Dec 20, 2022 10:00 HKT
田中貴金屬工業投資旨在建立日本醫療風險生態系統的風險投資基金「DMC1號投資事業有限合夥」
Dec 20, 2022 10:00 HKT
田中貴金屬工業投資旨在建立日本醫療風險生態系統的風險投資基金「DMC1號投資事業有限合夥」
Dec 20, 2022 10:00 HKT
中国抗体荣获“第七届金港股”评选中“最具价值医药及医疗公司”奖项
Dec 19, 2022 14:57 HKT
中國抗體榮獲「第七屆金港股」評選中「最具價值醫藥及醫療公司」獎項
Dec 19, 2022 14:56 HKT
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"
Dec 19, 2022 14:55 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: